Clinical trials: Rhinitis Allergic
Allergic Rhinitis, Conjunctivitis
Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants
Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU)…
- Trial name
- NCT05430919
- Testing
- REGN5713, REGN5714, REGN5715
- Where
- 3 sites in Canada
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Seasonal Allergic Rhinitis
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)
- Trial name
- NCT00740792
- Testing
- azelastine HCl/fluticasone propionate, azelastine Hcl, fluticasone propionate
- Where
- 39 sites in United States
- Volunteers
- 776 people
- Sponsor
- Meda Pharmaceuticals
Allergic Rhinitis
Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis
Primary aim is to evaluate the efficacy of specific immunotherapy with Pangramin SLIT HDM-mix compared to placebo in the treatment of House Dust Mite (HDM) induced rhinitis with or without asthma.
- Trial name
- NCT01603056
- Testing
- Pangramin SLIT HDM mix.
- Where
- China
- Volunteers
- 617 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinoconjunctivitis, Grass Pollen Allergy
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
The primary objective of this study is to assess whether the combination of grass allergen sublingual immunotherapy (SLIT) and dupilumab for 2 years is more effective than double placebo in suppressing the nasal allergen…
- Trial name
- GRADUATE (NCT04502966)
- Testing
- Dupixent®, Grazax®
- Where
- United Kingdom
- Volunteers
- 199 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rhinitis, Allergic, Seasonal
Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine
The primary objective of this study is to compare the nighttime symptom relief of fluticasone furoate nasal spray and oral fexofenadine
- Trial name
- NCT00435461
- Testing
- Fluticasone furoate and fexofenadine
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline
Seasonal Allergy
Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen
The primary objective of this study is to demonstrate the superiority of 2L®ALERG over placebo in terms of efficacy on the symptoms of allergic rhinitis and allergic rhinoconjunctivitis in patients with seasonal allergy to grass…
- Trial name
- LLB-2016-01 (NCT02690935)
- Testing
- 2LALERG
- Where
- Belgium
- Volunteers
- 102 people
- Sponsor
- Labo'Life
Rhinitis, Allergic, Perennial and Seasonal
A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis
This phase IV investigational trial is being conducted to evaluate the efficacy of a 2-week treatment of fluticasone propionate nasal spray (FPNS) vs.
- Trial name
- NCT01916226
- Testing
- FPNS, Cetirizine
- Where
- 31 sites in United States
- Volunteers
- 682 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)
The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).
- Trial name
- NCT01783548
- Testing
- BDP Nasal Aerosol
- Where
- 63 sites in United States
- Volunteers
- 547 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma, Allergic Rhinitis
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.
- Conditions
- Asthma, Allergic Rhinitis, Atopic Dermatitis
- Trial name
- Xolair (NCT00367016)
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, Davis